BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
November 13 2022 - 7:30PM
- First mRNA manufacturing facility in Singapore will create
regional manufacturing capacities in support of BioNTech’s growing
pipeline of mRNA-based vaccines and therapeutics across Asia
Pacific region for both clinical and commercial scale
- State-of-the art facility is expected to be fully operational
in late 2023, and to create more than 100 jobs
- Acquisition marks the next step in BioNTech’s plans to
establish a regional hub in the Asia Pacific Region
MAINZ, GERMANY, and SINGAPORE, November 14,
2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”)
today announced its Singapore affiliate BioNTech Pharmaceuticals
Asia Pacific Pte. Ltd. had entered into an agreement with Novartis
Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of
its GMP-certified manufacturing facilities. The acquisition is part
of BioNTech’s expansion strategy to strengthen its global footprint
in Asia. Supported by the Singapore Economic Development Board
(“EDB”), the facility will serve as BioNTech’s Regional
Headquarters and become its first mRNA manufacturing facility in
Singapore.
“We are excited to be moving a step closer to
expanding our global manufacturing network to Singapore, supporting
production of mRNA-based vaccines and therapeutics for the Asia
Pacific region. The acquisition gives us the opportunity to
accelerate the establishment of a state-of-the-art mRNA
manufacturing facility and thus to create capacity more quickly for
potential clinical studies and commercial supply of our mRNA
vaccines and therapeutics for the region,” said Dr Sierk
Poetting, Chief Operating Officer of BioNTech. “In the coming
months, we will work closely with all parties on the smooth
transition of the site as we continue to prepare for the
launch.”
“We are delighted that BioNTech has chosen
Singapore as the location for its new Regional Headquarters and
first mRNA manufacturing facility in the Asia Pacific region. The
company’s investment demonstrates confidence in the strong talent
base and deep manufacturing capabilities of our biopharmaceutical
ecosystem. BioNTech’s presence will enhance Singapore’s mRNA
capabilities and enable us to strengthen future pandemic
preparedness across the region,” said Ms. Goh Wan Yee, Senior
Vice President and Head, Healthcare, EDB.
BioNTech’s Singapore mRNA manufacturing facility
will create regional manufacturing capacities in support of
BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics
across Asia Pacific region for both commercial and clinical scale,
with the potential to expand the production to other drug classes,
such as cell therapies. The facility will be initially equipped to
manufacture a range of mRNA-based product candidates as well as
authorized vaccines and therapeutics for infectious diseases. This
may include the Company’s COVID-19 vaccine, as well as oncology
product candidates if successfully developed and approved or
authorized by regulatory authorities.
The site will be a fully integrated mRNA
manufacturing facility bringing mRNA production capabilities across
drug substance and drug product, with an expected annual production
capacity of up to several hundred million doses of mRNA-based
vaccines after a full built-out. It is expected to create more than
100 jobs in Singapore by 2024 across multiple functions, including
operations, engineering, quality, finance, human resources, as well
as supply chain management, with recruiting starting immediately
for first positions. The plant will be part of BioNTech’s affiliate
BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. and be fully
integrated into the Company’s global manufacturing network.
About BioNTechBiopharmaceutical New
Technologies is a next generation immunotherapy company pioneering
novel therapies for cancer and other serious diseases. The Company
exploits a wide array of computational discovery and therapeutic
drug platforms for the rapid development of novel
biopharmaceuticals. Its broad portfolio of oncology product
candidates includes individualized and off-the-shelf mRNA-based
therapies, innovative chimeric antigen receptor T cells, bispecific
immune checkpoint modulators, targeted cancer antibodies and small
molecules. Based on its deep expertise in mRNA vaccine development
and in-house manufacturing capabilities, BioNTech and its
collaborators are developing multiple mRNA vaccine candidates for a
range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global pharmaceutical collaborators, including
Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron,
Genevant, Fosun Pharma, and Pfizer. For more information, please
visit www.BioNTech.com.
BioNTech Forward-looking StatementsThis
press release contains “forward-looking statements” of BioNTech
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements may include, but may not
be limited to, statements concerning: BioNTech’s plans for
expansion of its manufacturing capacity and capabilities,
facilities, and geographical presence; BioNTech’s expected product
sales and revenues; the consummation and anticipated costs,
benefits and synergies of BioNTech’s expansion in Singapore; and
BioNTech’s ability to effectively scale its production capabilities
and manufacture its products, including BioNTech and Pfizer’s
COVID-19 vaccine, and BioNTech’s product candidates. Any
forward-looking statements in this press release are based on
BioNTech’s current expectations and beliefs of future events. The
forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond BioNTech’s control, and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements.
For a discussion of these and other risks and
uncertainties, see BioNTech’s Quarterly Report as Form 6-K for the
quarter ended September 30, 2022, filed with the SEC on November 7,
2022, which is available on the SEC’s website at www.sec.gov. All
information in this press release is as of the date of the release,
and BioNTech undertakes no duty to update this information unless
required by law.
CONTACTS
Media RelationsJasmina Alatovic+49
(0)6131 9084 1513Media@biontech.de
Investor RelationsSylke Maas, PhD.+49
(0)6131 9084 1074Investors@biontech.de
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From Apr 2024 to May 2024
BioNTech (NASDAQ:BNTX)
Historical Stock Chart
From May 2023 to May 2024